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Background: Cyclophosphamide (Cy) is a prodrug met-
abolized by hepatic cytochrome p450 enzymes into active
cytotoxin. High dose Cy-containing chemotherapy followed
by autologous hematopoietic cell transplant (autoHCT) is
often curative for patients with lymphoma; however, relapse
occurs in about 50% of patients. We investigated the associ-
ation between genetic polymorphisms in Cy metabolism and
outcomes after autoHCT for lymphoma.
Material and Method: We studied lymphoma patients
who received myeloablative Cy-containing conditioning be-
tween 2004-2012 with available DNA samples. Somatic DNA
was obtained from pre-transplant bone marrow aspirates,
and Sequenom and Taqman genotyping assays were used
to analyze 22 genes and 38 single nucleotide polymorphisms
(SNP) involved in Cy metabolism. All patients were followed
for at least one year. The association of each SNP with overall
survival (OS) and disease-free survival (DFS) following
autoHCT was analyzed using multivariable Cox regression,
with categorical factors for genotype, age ( 55 vs.
< 55 years), and gender. A separate model was used for each
SNP. P-values were corrected for multiple testing using the
Holm method.
Results: We studied 93 patients (median age 45 years) with
lymphoma (52 Hodgkin, 21 diffuse large B cell, 12 mantle
cell, 8 others); 55% were male. Two-thirds received Cy
(120 mg/kg) combined with BCNU/etoposide conditioning
and a third received Cy (6000 mg/ m2) with total body
irradiation (1250 cGy). The majority (96%) had chemo-
sensitive disease with 61% in complete remission pretransplant. Two year DFS and OS for the entire cohort was
60% (95%CI 49-69%) and 86% (95%CI 76-91%), respectively. A
single SNP rs3211371 in the CYP2B6 gene signiﬁcantly
impacted survival. This SNP results in Arg487Cys and
inﬂuences CYP2B6 activity. Adjusted for age and gender,
patients heterozygous (CT; n¼69) for SNP rs3211371 had
signiﬁcantly better DFS (HR 0.27; 95%CI 0.13- 0.56 ; p¼0.024)
and OS ( HR 0.09; 95%CI: 0.02-0.35; p¼0.03) as compared to
homozygous patients (TT; n¼21). This association was not
confounded by age, gender, disease type, conditioning, or
remission status.
Conclusion: Our results show a strong association between
CYP2B6 rs3211371 SNP and survival in lymphoma patients
treated with high-dose Cy and autoHCT. We plan to evaluate
serum levels of Cy active metabolites and conﬁrm the
potency of this association in a larger study.
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Introduction: High-dose therapy with AutoHCT is a
standard component of therapy for many patients with
Hodgkin lymphoma (HL) and non-Hodgkin lymphoma
(NHL). Choice of high-dose therapy regimens has historically
been driven by institutional tradition. No randomized
prospective clinical trials have shown a difference in out-
comes between conditioning regimens.
Methods: Using the Center for International Bone Marrow
Transplant Registry (CIBMTR), we studied 4,917 patients
with lymphoma (NHL n¼3,905; HL n¼ 1,012) who under-
went AutoHCT from 1995-2008 using the most commonly
used conditioning regimens: BEAM (n¼1730), CBVlow
(n¼1249), CBVhigh (n¼604), BuCy (n¼789), and TBI (n¼545)-
based regimens. The CBV cohort was divided based on
the BCNU dose and its impact on outcome (above [high] vs.
below [low] 375 mg/m2).
Results: The cohorts differed in: age <54y (BEAM 47%,
CBVlow 61%, CBVhigh 66%, BuCy 50% and TBI 60%), HL (BEAM
18%, CBVlow 23%, CBVhigh 37%, BuCy 21% and TBI 4%) and year
of transplant 2002 (BEAM 70%, CBVlow 18%, CBVhigh 26%,
BuCy 49% and TBI 19%). 1-year rates of TRM ranged from 4%
Groups HL Progression Overall Mortality
N HR (95% CI) p-value HR (95% CI) p-value
BEAM 313 1.00 - 1.00 -
CBVlow 279 1.12 (0.85-1.47) 0.43 1.53 (1.16-2.02) 0.003
CBVhigh 219 0.95 (0.71-1.28) 0.74 1.54 (1.15-2.05) 0.003
BuCy 162 1.52 (1.13-2.05) <0.001 1.77 (1.30-2.43) <0.001
TBI 23 1.94 (1.09-3.45) 0.024 3.39 (2.03-5.64) <0.001
Table 1
Patient Characteristics and Outcome
13q (n¼42) 13q+ (n¼34)
Age (years) 65 (88-44) 13q+ (n¼34)
Gender
Male 19 (45%) 15
Female 23 (55%) 19 (55%)
Race
White 13 (30%) 11 (32%)
African American 27 (65%) 20 (60%)
Other 2 3
International Staging System at diagnosis
I 5 (15%)
II 3 (7%) 4 (12%)
III 26 (62%) 30 (88%)
Plamacytoma 9 (21%) 12 (35%)
Bortezomib based Induction
Regimen 14 (33%) 13 (38%)
Conditioning regimen Melphlan 16 (38%) 7 (20%)
IgG 21 (51%) 19 (56%)
IgA 8 (20%) 9 (26%)
IgM 4 (9%)
Mortality 13 (31%) 21 (62%)
Overall survival 65% 25%
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analysis. There were a signiﬁcant interaction between regi-
mens and disease (HL and NHL). For patients with NHL, there
was no signiﬁcant difference in outcomes with BEAM,
CBVlow, BuCy, and TBI. In contrast, NHL patients treated with
CBVhigh had higher progression (HR 1.28 [1.08, 1.50],
p¼0.003), and mortality (HR 1.27 [1.08, 1.49], p¼0.003). For
patients with HL, BuCy and TBI were associated with higher
progression at 3 years compared to BEAM (47%, 57% vs. 36%)
and shorter overall survival (65%, 47% vs. 79%). Multivariable
results for HL are demonstrated in the table.
Conclusion: The impact of speciﬁc high-dose regimens
with AutoHCT on overall outcomes appears to be different in
patients with NHL and HL. Use of CBVhigh in patients with
NHL and BuCy or TBI-containing regimens in HL were asso-
ciated with worse outcomes compared to BEAM. Future
investigation should be geared towards guiding the choice of
regimen based on speciﬁc patient and disease characteristics.37
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Background: Chromosomal abnormalities detected by
interphase ﬂuorescence in situ hybridization (I-FISH) are
an important prognostic marker in patients with multiple
myeloma (MM). Isolated chromosome 13q has been
considered standard risk when identiﬁed by I-FISH and high
risk by conventional cytogenetics. The impact of additional
cytogenetic abnormalities with chromosome 13q identiﬁed
by I-FISH in regards to prognosis has not been fully deﬁned.
In this report, we describe the outcome of patient’s with
multiple myeloma with isolated chromosome 13q and 13q+
(additional cytogenetic abnormalities) identiﬁed by I-FISH at
our institution between January 2003 and January 2013 and
had I-FISH analysis prior to treatment.
Methods: The primary objective was to compare patient’s
outcomes in regards to response, time to progression, and
overall survival between patients who had an isolated 13q
and 13q+ identiﬁed by I-FISH in the bone marrow plasma
cells. Kaplan & Meier curves were generated to calculate
overall survival (OS) between the two groups.
Results: Between January 2003 and January 2013, we iden-
tiﬁed 76 patients by I-FISH who had either an isolated 13q or
13q+ in patients with multiple myeloma (Patient chara-
cteristics Table 1). Of the patients with an isolated 13q
abnormality 33% received a bortezomib-based regimen and
38% in the 13q+ group. Of the patient’s with a isolated 13q
38% went onto receive high dose chemotherapy followed
by autologous ASCT while 20% with a 13q+ received ASCT.African American patients with 13q consisted of 65% and
60% with 13q+ in our patient population. For the 13q or
13q+ who underwent high dose chemotherapy followed
by ASCT OS was 85% compared to the non-transplant
group 45% (p¼0.01) (Figure 2). On follow up at a median of
2.5 years mortality occurred in 31% of the 13q patients
compared to 62% in the 13q+ group. The overall survival at
5 years was 25% in the 13q+ group compared to 65% in the
patient’s with an isolated 13q, With the 13q+ group having
an overall poor OS (p¼0.03)
Conclusion: Patients who harbor the 13q and additional
cytogenetic abnormalities identiﬁed by I-FISH have a signif-
icant worse outcome compared to patients with an isolated
13q. These patients should be considered high risk and
consideration for treatment with novel agents and autolo-
gous stem cell transplant followed by post-transplant
maintenance therapy should be considered.
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Background: Hepatitis B core antibody (HBcAb) seroposi-
tivity has been associated with a higher rate of hepatitis
B reactivation after chemotherapy, even in patients who are
hepatitis B surface antigen (HBsAg)-negative. We evaluated
the incidence of hepatitis B reactivation and liver toxicity
in patients with multiple myeloma (MM) who received
high-dose chemotherapy (HDC) and autologous hematopoi-
etic stem cell transplantation (auto-HCT) at our institution.
